Dr Reddy’s settles patent litigation with Indivior, Aquestive Therapeutics

On June 28, 2022, a US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.

Dr Reddys, Dr Reddy labs, health news, pharma news,
Moreover, the combined sales as per internal estimates were INR 33 crores for FY 2021-22, the company revealed.

Dr Reddy’s Laboratories on Thursday said it has settled patent litigation with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction. On June 28, 2022, a US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.

The stipulation of dismissal was filed pursuant to a settlement agreement that the company entered into with Indivior and Aquestive, it added. “The settlement and dismissal resolve all claims between the parties, including Indivior’s and Aquestive’s claims for patent infringement as well as the company’s antitrust counterclaim against Indivior,” Dr Reddy’s said.

On June 24, Dr Reddy’s announced that it has entered into a settlement agreement with Indivior Inc and Aquestive Therapeutics as a result of which it will receive payments totalling USD 72 million by March 31, 2024. The said agreement resolves all claims between the parties relating to the company’s generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, it had said. Buprenorphine and naloxone sublingual film medication is used to treat opioid dependence or addiction.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Most Read In Healthcare
Photos